glp 1 glp 2 GLP-1 receptor agonists The Discovery of GLP-2 and
Description
Christensen, L., Roager, H

Quick Answer: No, commercially available GLP-1 patches have not been proven effective and lack FDA approval for weight loss or diabetes management

In the subsequent phase III STEP trials of semaglutide, 2.4 mg once weekly, carefully up-titrated over 20 weeks, average weight losses of up to 18% were achieved over 68 weeks in people with obesity (start weight 107 kg) [40]

This review will use the term MASLD, defined as the presence of hepatic steatosis with no other discernible cause, in conjunction with at least one cardiometabolic risk factor (CMRF), such as type 2 diabetes mellitus (T2DM), obesity, hypertension, or dyslipidemia
However, at this point it should be noted that different incretin drugs are characterized by different pharmacokinetics, and therefore, they are taken by patients at different time intervals

You May Need a Different Medication Not all GLP-1 medications work the same way
